Student Brings Panel of AIDS Quilt to UNC

As a freshman at UNC, Elizabeth Trefney remembers seeing a flyer publicizing a class about HIV/AIDS. The semester-long course is offered each spring by the UNC Center for AIDS Research (CFAR) and is open to all students. Past classes have focused on how the virus impacts the immune system, currently available treatments and the latest… Read More

Global Health: What’s in It for Us?

Satish Gopal, MD, MPH, directs the cancer program at UNC Project-Malawi. He is the only medical oncologist in Malawi, a nation of more than 18 million people. He has received two developmental and two supplemental awards through the UNC CFAR to support his research. Yet, when his daughter became sick with malaria recently, he paused… Read More

NIH Increases Funding for iTech Center

The National Institutes of Health (NIH) has awarded the UNC/Emory Center for Innovative Technology (iTech) an additional $13 million to develop interventions for youth at risk for or living with HIV. “iTech will serve as the first NIH-funded center to use technology in innovative ways to engage HIV infected or at-risk youth,” says Principal Investigator… Read More

Hudgens Co-edits Book on Quantitative Methods

Michael Hudgens, PhD, professor of biostatistics at the UNC Gillings School of Global Public Health, is co-editor of a new book, Quantitative Methods for HIV/AIDS Research, published Aug. 15 by CRC Press. The text brings together the perspectives of statisticians and mathematicians engaged in research on HIV/AIDS. “We hope that the work will inspire more… Read More

Eron Named Vice Chair of Largest NIH HIV Research Network

UNC Professor of Medicine Joseph Eron, MD, has been elected vice chair of the AIDS Clinical Trials Group (ACTG). Established by the National Institutes of Health (NIH) in 1987, the ACTG is the largest network of research sites in the world dedicated to finding a cure for HIV and the virus’s opportunistic infections. “The ACTG… Read More

UNC to Test Therapeutic HIV Vaccine

A multidisciplinary research team at the University of North Carolina at Chapel Hill has been awarded more than $5.6 million from the National Institutes of Health (NIH) to test a therapeutic vaccine in people living with HIV. Strengthening and redirecting the immune system’s anti-HIV response are the primary goals of the five-year study. “The first… Read More

Vorinostat Dosing Exposes Latent HIV

Exposing hidden HIV reservoirs so that they can be cleared is a strategy being tested in efforts to develop therapies to cure the nearly 40 million people worldwide living with HIV. Researchers at the University of North Carolina at Chapel Hill have shown that interval dosing of the drug Vorinostat reverses HIV latency and is… Read More